AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.720

-0.015-0.86%

Volume:7.84M

Turnover:13.14M

Market Cap:2.20B

PE:-12.07

High:1.725

Open:1.650

Low:1.630

Close:1.735

Loading ...

Overview Company News Filings

Up 77% in a month! What's going on with the Mesoblast share price?

Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%

MT Newswires Live

Here's how the Vanguard Australian Shares Index ETF performed in 2024

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Exploring 3 High Growth Tech Stocks In Australia

Simply Wall St.

Why Appen, Brainchip, Liontown, and Mesoblast shares are falling today

5 ASX All Ords shares starting the new year at 52-week highs

ASX Market Close: Bourse defies red futures to end up on 2025’s first trading day | Jan 2, 2024

The Market Herald

Why Brainchip, Fortescue, Mesoblast, and QBE shares are racing higher today

Did you own the 5 best ASX All Ordinaries shares of 2024?

Why DroneShield, Invictus Energy, Mesoblast, Weebit Nano shares are rising today

Gold Medal Awards: All the biggest ASX winners (and top stock gainers) in 2024

The Market Herald

Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher

Mesoblast Cut to Hold From Buy by Jefferies

Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30

MT Newswires Live

US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says

MT Newswires Live

Shares vs. property: Biggest investment trends of 2024

Galloping to the top of the runners of the week podium is… icetana

The Sydney Morning Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.72,"timestamp":1746598320000,"preClose":1.735,"halted":0,"volume":7835671,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":784305641,"shares":1277239284,"eps":-0.14247791710420654,"marketStatus":"Closed","change":-0.015,"latestTime":"05-07 16:12:00 AEST","open":1.65,"high":1.725,"low":1.63,"amount":13136134,"amplitude":0.054755,"askPrice":1.72,"askSize":5187,"bidPrice":1.71,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-0.14247791710420654,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746662400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.735,"openAndCloseTimeList":[[1746576000000,1746597600000]],"volumeRatio":1.957158,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":784305641,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.137657,"volumeRatio":1.957158,"shares":1277239284,"dividePrice":0,"high":1.725,"amplitude":0.054755,"preClose":1.735,"low":1.63,"week52Low":0.88,"pbRate":"3.08","psRate":"250.90","week52High":3.37,"institutionHeld":0,"latestPrice":1.72,"committee":0.148765,"eps":-0.14247791710420654,"divideRate":0,"volume":7835671,"delay":0,"ttmEps":-0.14247791710420654,"open":1.65,"prevYearClose":3.1,"prevWeekClose":1.845,"prevMonthClose":1.795,"prevQuarterClose":1.96,"fiveDayClose":1.795,"twentyDayClose":1.765,"sixtyDayClose":3.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501217172","title":"Up 77% in a month! What's going on with the Mesoblast share price?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501217172","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501217172?lang=en_us&edition=fundamental","pubTime":"2025-01-07 11:04","pubTimestamp":1736219078,"startTime":"0","endTime":"0","summary":"The gains that we've seen in the Mesoblast share price in recent weeks all stem from the blockbuster news that Mesoblast shared just before Christmas. As we covered back on 19 December, Mesoblast finally received the green light from the US Food and Drug Administration  for its Ryoncil  product. Ryoncil is a treatment for the deadly steroid-refractory acute graft versus host disease . It is the only therapy that has gained approval for use in children two months and older in the United States. Mesoblast has been preparing for this FDA decision throughout 2024. Optimism that the company would gain approval arguably fuelled much of the gains in the Mesoblast share price in the first half of the year. But the official green light really lit a rocket under the Mesoblast share price. On the day that this news became public, Mesoblast shares soared a whopping 54%. The company has continued to trend upwards  ever since. So the Mesoblast share price is entering 2025 at a notable high. Let's se","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/up-77-in-a-month-whats-going-on-with-the-mesoblast-share-price/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","XAO.AU","BK7067","BK7501","MSB.AU","MESO","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2501907092","title":"Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501907092","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501907092?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:48","pubTimestamp":1736210882,"startTime":"0","endTime":"0","summary":"Mesoblast  will issue 10.2 million ordinary shares to Osiris Therapeutics as contingent consideration in relation to the approval of its cell treatment by the US Food and Drug Administration , according to a Monday Australian bourse filing.The FDA approved the firm's mesenchymal stromal cell therapy, Ryoncil, in December 2024, according to an earlier filing.The shares will be subject to voluntary escrow for 12 months from the date of issue, the filing said.Mesoblast's shares fell 6% during trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MSB.AU","BK7508","BK7067","MESO","BK7501","LENZ"],"gpt_icon":0},{"id":"2500125597","title":"Here's how the Vanguard Australian Shares Index ETF performed in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500125597","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500125597?lang=en_us&edition=fundamental","pubTime":"2025-01-04 04:00","pubTimestamp":1735934400,"startTime":"0","endTime":"0","summary":"The Vanguard Australian Shares Index ETF (ASX: VAS) delivered a total gross return of 11.4% in 2024.  This comprised approximately 7.75% in capital growth and a dividend yield of about 3.65%, excludin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/04/heres-how-the-vanguard-australian-shares-index-etf-performed-in-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","BK7508","NXL.AU","MSB.AU","SLC.AU","BK7094","SPR.AU","ZIP.AU","BK4585","XKO.AU","VAS.AU","BK4588","BK7093","SIG.AU","BK7116","IPX.AU","FDN","BK7501","XJO.AU","BK4550","TLX.AU","360.AU","PME.AU","XAO.AU","BK7104","BK7015","ETF.AU","BK7067","BK7103"],"gpt_icon":0},{"id":"2500141989","title":"MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2500141989","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500141989?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:56","pubTimestamp":1735919760,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease  in children aged two months and older, including adolescents and teenagers. The drug has a novel mechanism of action and will be marketed under the brand name Ryoncil in the United States.The approval gave Mesoblast its first approved product in its portfolio. Sales of the drug are expected to provide the company with a steady source of income. The company is currently gearing up to launch the product in the U.S. market.SR-aGVHD is a devastating condition that has an extremely poor prognosis. Each year in the United States, around 10,000 patients, including 1,500 children, undergo allogeneic bone marrow transplants. About 50% develop aGvHD, and nearly half of these cases are steroid-resistant.In the past six months, shares of Mesoblast have skyrocketed 202.9% against the industry’s 4.8% decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","BK4139","CSTL","CTMX","BK4196","SPRO","MESO"],"gpt_icon":0},{"id":"2500158639","title":"Exploring 3 High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2500158639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500158639?lang=en_us&edition=fundamental","pubTime":"2025-01-03 12:07","pubTimestamp":1735877241,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions.Click here to see the full list of 60 stocks from our ASX High Growth Tech and AI Stocks screener.Underneath we present a selection of stocks filtered out by our screen.Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$602.36 million.Operations: Clinuvel Pharmaceuticals generates revenue primarily from its biopharmaceutical sector, amo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-high-growth-tech-040721425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7501","XJO.AU","MSB.AU","MESO","XKO.AU","BK7016","CUV.AU","BK7067","XAO.AU","BK7508","FCL.AU"],"gpt_icon":0},{"id":"2500180955","title":"Why Appen, Brainchip, Liontown, and Mesoblast shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2500180955","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500180955?lang=en_us&edition=fundamental","pubTime":"2025-01-03 09:01","pubTimestamp":1735866063,"startTime":"0","endTime":"0","summary":"In early afternoon trade, theS&P/ASX 200 Index(ASX: XJO) has found its legs after a subdued start and is pushing higher. At the time of writing, the benchmark index is up 0.4% to 8,235.3 points. Four ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/why-appen-brainchip-liontown-and-mesoblast-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["APX.AU","BK4150","BK7016","BK4139","BK7503","LTR.AU","BK7061","BK7508","MESO","MSB.AU","BK7067","BRN.AU","MSC","BK4575","BK7501","BK7095","BK7504","XJO.AU"],"gpt_icon":0},{"id":"2500680904","title":"5 ASX All Ords shares starting the new year at 52-week highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2500680904","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500680904?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:00","pubTimestamp":1735851600,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords Index  shares closed higher on the first day of trading for 2025.The ASX All Ords finished 0.53% higher at 8,465 points on Thursday.Here are five ASX All Ords shares that started the new year on a positive note with 52-week high prices.5 ASX All Ords shares that hit 52-week highs on Thursday. It's rather fitting that the No. 1 stock among the 5 best-performing ASX All Ords stocks of 2024 started the new year at a four-year high.The Mesoblast share price reached $3.37 in intraday trading on Thursday.However, the ASX All Ords stock has been on an upward trajectory since the biotech gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.Branded Ryoncil, the drug is the first approved treatment for steroid-refractory acute graft versus host disease  in children and the first mesenchymal stromal cell  therapy approved in the US.Another ASXAll Ords techshare, Bravura Solutions, also clocked a 52-week high yesterday.AS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/5-asx-all-ords-shares-starting-the-new-year-on-52-week-highs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PRN.AU","MSC","BK7095","BK7502","BK4575","BOT.AU","BK7096","XAO.AU","BK7501","APX.AU","BK7067","BK7503","BVS.AU","MSB.AU","BK4150","BK7508","BK7016","BK7061"],"gpt_icon":0},{"id":"2500399010","title":"ASX Market Close: Bourse defies red futures to end up on 2025’s first trading day | Jan 2, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500399010","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500399010?lang=en_us&edition=fundamental","pubTime":"2025-01-02 13:14","pubTimestamp":1735794840,"startTime":"0","endTime":"0","summary":"The local bourse has defied morning predictions to end 34 points up, at 8,189  after ASX 200 futures originally suggested a dive of as much as 1%.Nearly every sector was in the green through Thursday’s trade, including market-leading Energy, up 1.31%. It was followed closely by Real Estate, up 1.12%, as well as Materials, which added 1.02% up to 4pm Sydney time.That down sector was mostly due to shopping heavyweights Coles  and Woolworths  balancing each other with flat price movements.Mesoblast  – which HotCopper just flagged as 2024’s biggest winner – has added another 7.10% today, to $3.32, as excitement gripped the trading community there. The medicine company has been nigh-unstoppable since it just recently locked in FDA approval for its U.S. expansion push.Paladin Energy  and Fortescue Ltd  were other big winners through January’s first trade day, adding 4.23% and 3.10% respectively.Lycaon Resources  was one of the biggest movers through the day, lifting 66.7%  after it was confi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-bourse-defies-red-futures-to-end-up-on-2025s-first-trading-day-jan-2-2024-2025-01-02/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["COL.AU","BK7067","BK7083","WOW.AU","LYN.AU","BK7129","BK7507","GCM.AU","BK7098","BK7040","PDN.AU","BK7069","GYG.AU","FMG.AU","BK7095","BK7509","ERA.AU","BK7511","BK7508","BK7082","MSB.AU","BK7501","WBT.AU","BK7137"],"gpt_icon":0},{"id":"2500697309","title":"Why Brainchip, Fortescue, Mesoblast, and QBE shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2500697309","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500697309?lang=en_us&edition=fundamental","pubTime":"2025-01-02 09:54","pubTimestamp":1735782891,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on course to start the year with a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,192.9 points. Four ASX shares that are rising more than m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/02/why-brainchip-fortescue-mesoblast-and-qbe-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK4139","BK7507","BRN.AU","BK4575","MSB.AU","XJO.AU","BK7129","MSC","BK7034","BK4150","BK7508","QBE.AU","FMG.AU","BK7501","BK7016","MESO"],"gpt_icon":1},{"id":"2500959607","title":"Did you own the 5 best ASX All Ordinaries shares of 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500959607","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500959607?lang=en_us&edition=fundamental","pubTime":"2025-01-02 05:53","pubTimestamp":1735768389,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index (ASX: XAO) shares rose by 7.55% in 2024 to finish the year at 8,420.5 points on 31 December. The total gross return, including dividends, was 11.44%.  The ASX All Ords sli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/02/did-you-own-the-5-best-asx-all-ordinaries-shares-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","BK7501","BK4150","BK7061","MSB.AU","IPX.AU","MSC","XAO.AU","APX.AU","BK7116","BK7503","XJO.AU","BK4575","BK7093","ZIP.AU","BK7067","BK7508","NXL.AU"],"gpt_icon":1},{"id":"2495891506","title":"Why DroneShield, Invictus Energy, Mesoblast, Weebit Nano shares are rising today","url":"https://stock-news.laohu8.com/highlight/detail?id=2495891506","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495891506?lang=en_us&edition=fundamental","pubTime":"2024-12-31 09:01","pubTimestamp":1735606911,"startTime":"0","endTime":"0","summary":"In early afternoon trade, theS&P/ASX 200 Index(ASX: XJO) is on course to finish the year with another decline. At the time of writing, the benchmark index is down 0.7% to 8,174.7 points. Four ASX shar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/31/why-droneshield-invictus-energy-mesoblast-weebit-nano-shares-are-rising-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7069","MESO","DRO.AU","BK7501","IVZ.AU","BK7098","BK4150","BK7508","XJO.AU","BK7142","MSB.AU","BK7067","BK7115","MSC","WBT.AU","BK4139","BK4575"],"gpt_icon":0},{"id":"2500314719","title":"Gold Medal Awards: All the biggest ASX winners (and top stock gainers) in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500314719","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500314719?lang=en_us&edition=fundamental","pubTime":"2024-12-31 08:40","pubTimestamp":1735605600,"startTime":"0","endTime":"0","summary":"The ASX is barrelling towards closing out 2024 with another red day on New Year’s Eve, but that doesn’t mean the year as a whole was a bloodbath – in fact, for much of the Aussie index it’s been quite the year to remember.Even more so, some Australian companies have beaten the milestone marker , which was up 8.51% YTD across the board.While nearly 10% up is a very respectable jump, we’re talking big, big leaps to close out the year and that means a dozen of the biggest winners across the bourse. These range from investment groups to biotech victors, and even  a buy now, pay later heavyweight that always draws HotCopper eyes.Here are some of the many winners that made it through 2024 well in the green.Opening our HotCopper winner picks, Hub24 is celebrating 2024 after the investment platform provider raked in more than $4 billion in recent quarters.The heavy push into titanium paid off for IperionX this year, especially after it finished work on its HAMR furnace in Virginia; a more than","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/gold-medal-awards-all-the-biggest-asx-winners-and-top-stock-gainers-in-2024-2024-12-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ZIP.AU","BK7067","BK7016","IPX.AU","SPR.AU","BK7062","BK7508","BK7158","360.AU","BK7093","TLX.AU","FND.AU","PNI.AU","BK7103","MSB.AU","BK7043","BK7094","PME.AU","BK7501","BK7054","BK7104","NXL.AU","BK7116","HUB.AU","SIG.AU"],"gpt_icon":0},{"id":"2494845946","title":"Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2494845946","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494845946?lang=en_us&edition=fundamental","pubTime":"2024-12-27 09:21","pubTimestamp":1735262468,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on form again after returning from the Christmas break. At the time of writing, the benchmark index is up 0.4% to 8,255.7 points. Four ASX shares that are rising mor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/27/why-bowen-coal-droneshield-mesoblast-and-st-barbara-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7501","BK4150","MSC","BCB.AU","BK7115","MESO","BK7104","BK7506","BK7129","XJO.AU","BK4575","BK4139","DRO.AU","BK7067","BK7508","SBM.AU"],"gpt_icon":1},{"id":"2494451860","title":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2494451860","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494451860?lang=en_us&edition=fundamental","pubTime":"2024-12-26 23:29","pubTimestamp":1735226940,"startTime":"0","endTime":"0","summary":"The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance and pipeline setbacks. These challenges highlighted the inherent volatility in biotech, amplified by broader macroeconomic uncertainties. Despite these setbacks, the demand for cutting-edge medical innovations ensures the sector remains a focal point for investors.Looking ahead, innovation will continue to be a key growth driver, particularly in high-potential areas like obesity and oncology treatments. The sector's robust fundamentals and expectations of strong M&A activity in 2025 indicate a promising outlook. While the current environment may deter some, the long-term need for advanced medicines is expected to draw investors back to the sector, reinforcing its importance in the healthcare landscape.As we approach the New Year, let us take a good look at some biotech companies likeAr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/awaits-4-biotech-stocks-more-152900258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARQT","MSB.AU","KOD","BK4505","MESO","BK4139","MNPR"],"gpt_icon":0},{"id":"2493700746","title":"Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2493700746","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493700746?lang=en_us&edition=fundamental","pubTime":"2024-12-24 09:02","pubTimestamp":1735002147,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is having a volatile session but is currently on course to record a small gain. In early afternoon trade, the benchmark index is up slightly to 8,208.5 points. Four AS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/24/why-avita-medical-genusplus-mesoblast-and-polynovo-shares-are-storming-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7508","MSC","AVH.AU","BK7067","GNP.AU","XJO.AU","BK7055","BK4150","MESO","BK7501","PNV.AU","BK4575","BK4139","BK7126"],"gpt_icon":0},{"id":"2493759384","title":"Mesoblast Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2493759384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493759384?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:07","pubTimestamp":1734955620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 07:07 ET (12:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK4139","MSB.AU","BK7508","BK7501","MESO"],"gpt_icon":0},{"id":"2493505736","title":"Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2493505736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493505736?lang=en_us&edition=fundamental","pubTime":"2024-12-23 17:05","pubTimestamp":1734944720,"startTime":"0","endTime":"0","summary":"Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2493520692","title":"US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2493520692","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493520692?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:19","pubTimestamp":1734923952,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration's approval of a mesenchymal stromal cell (MSC) therapy bodes well for Cynata Therapeutics (ASX:CYP), Euroz Hartleys said in a Dec. 19 note.Cynata Therapeutics focus","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","BK4139","BK4150","MSB.AU","MSC","CYP.AU","BK4575","LENZ","BK7501"],"gpt_icon":0},{"id":"2493318424","title":"Shares vs. property: Biggest investment trends of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493318424","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493318424?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:30","pubTimestamp":1734715800,"startTime":"0","endTime":"0","summary":"As another year of investing draws to a close, let's review the biggest trends in ASX shares vs. property.  First, let's take a macro view.  At the time of writing, the S&P/ASX 200 Index  is up 5.76% in the year to date . If we add the typical 4% dividend return on top, we get a total estimated return of 9.76%. The two best months of the year for share price gains have been July, when the ASX 200 rose 4.18%, and November, when it lifted 3.38%.  The ASX 200 has reset its all-time record high many times over throughout the year. The latest record was set on 3 December at 8,514.5 points. Meantime, the national home value rose for a 22nd consecutive month in November, according to CoreLogic data. It's now up 5.2% YTD, with total annual returns  tracking at 9.6%.  So, there's not much competition between shares vs. property in terms of overall returns in 2024. Based on current trends, both asset classes will deliver total returns of 9% to 10%. Very satisfactory!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/21/shares-vs-property-biggest-investment-trends-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","BHP.AU","BK7508","XJO.AU","ZIP.AU","XKO.AU","BK7016","BK7135","BK7501","BK7067","BK7095","BK7507","CBA.AU","MSB.AU","BK7511","BK7093","360.AU"],"gpt_icon":0},{"id":"2492049122","title":"Galloping to the top of the runners of the week podium is… icetana","url":"https://stock-news.laohu8.com/highlight/detail?id=2492049122","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492049122?lang=en_us&edition=fundamental","pubTime":"2024-12-20 17:04","pubTimestamp":1734685440,"startTime":"0","endTime":"0","summary":"Against a backdrop of jittery global stock markets – the United States Dow Jones has endured a 10-day losing streak – its worst since 1974 - this week’s batch of Runners have still managed to buck the broader trend with solid gains, led by news of an AI deal, a copper mine acquisition and a long-awaited FDA approval.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/galloping-to-the-top-of-the-runners-of-the-week-podium-is-icetana-20241220-p5l02x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["MSB.AU","BK7104","PAT.AU","BK7501","BK7067","BK7508","ICE.AU","BK7016","BDG.AU","BK7095"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}